مكتبة

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug-drug-gene interaction network.

Authors : Feick D; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.; Rüdesheim S

Subjects: Cytochrome P-450 CYP2D6*/Cytochrome P-450 CYP2D6*/Cytochrome P-450 CYP2D6*/genetics ; Cytochrome P-450 CYP2D6*/Cytochrome P-450 CYP2D6*/Cytochrome P-450 CYP2D6*/metabolism ; Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/genetics

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Aug; Vol. 12 (8), pp. 1143-1156. Date of Electronic Publication: 2023 May 23.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.

Authors : Pai SM; Clinical Pharmacology, Akros Pharma, Inc., Princeton, New Jersey, USA.; Yamada H

Subjects: Cytochrome P-450 CYP1A2*/Cytochrome P-450 CYP1A2*/Cytochrome P-450 CYP1A2*/metabolism ; Cytochrome P-450 CYP2D6*/Cytochrome P-450 CYP2D6*/Cytochrome P-450 CYP2D6*/metabolism; Humans

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Jul; Vol. 12 (7), pp. 667-682. Date of Electronic Publication: 2023 Jun 02.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.

Authors : Tolledo EC; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Department of Pharmacology & Toxicology, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.; Miksys S

Subjects: Cytochrome P-450 CYP2D6* ; Propranolol*/Propranolol*/Propranolol*/pharmacology; Cytochrome P-450 CYP2D6 Inhibitors/Cytochrome P-450 CYP2D6 Inhibitors/Cytochrome P-450 CYP2D6 Inhibitors/*pharmacology

Source: British journal of pharmacology [Br J Pharmacol] 2020 Feb; Vol. 177 (3), pp. 701-712. Date of Electronic Publication: 2020 Jan 06.Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration-QTc Analysis.

Authors : Schneider F; Teva Pharmaceutical Industries Ltd, Berlin, Germany.; Darpo B

Subjects: Cytochrome P-450 CYP2D6* ; Huntington Disease*/Huntington Disease*/Huntington Disease*/drug therapy; Adult

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Jan; Vol. 12 (1), pp. 94-106. Date of Electronic Publication: 2022 Sep 13.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups.

Authors : Rüdesheim S; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, University of Tübingen, Stuttgart, Germany.

Subjects: Cytochrome P-450 CYP2D6* ; Dextromethorphan*/Dextromethorphan*/Dextromethorphan*/pharmacokinetics; Dextrorphan

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Apr; Vol. 11 (4), pp. 494-511. Date of Electronic Publication: 2022 Mar 08.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity.

Authors : Magliocco G; Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.

Subjects: Cytochrome P-450 CYP2D6*/Cytochrome P-450 CYP2D6*/Cytochrome P-450 CYP2D6*/genetics ; Cytochrome P-450 CYP2D6*/Cytochrome P-450 CYP2D6*/Cytochrome P-450 CYP2D6*/metabolism ; Metabolomics*

Source: British journal of pharmacology [Br J Pharmacol] 2021 Dec; Vol. 178 (23), pp. 4708-4725. Date of Electronic Publication: 2021 Sep 09.Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects.

Authors : Trivedi A; Amgen Inc., Thousand Oaks, California, USA.; Malik FI

Subjects: Cytochrome P-450 CYP2D6* ; Cytochrome P-450 CYP3A*; Drug Interactions

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Feb; Vol. 11 (2), pp. 185-193. Date of Electronic Publication: 2021 Jun 19.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate.

Authors : Mohamed MF; AbbVie Inc., North Chicago, Illinois, USA.; Minocha M

Subjects: Bupropion/Bupropion/Bupropion/*pharmacokinetics ; Cytochrome P-450 CYP2B6/Cytochrome P-450 CYP2B6/Cytochrome P-450 CYP2B6/*drug effects ; Cytochrome P-450 CYP2D6 Inhibitors/Cytochrome P-450 CYP2D6 Inhibitors/Cytochrome P-450 CYP2D6 Inhibitors/*pharmacokinetics

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Mar; Vol. 10 (3), pp. 299-306. Date of Electronic Publication: 2020 Jul 09.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction.

Authors : Couffignal C; INSERM, IAME, Université de Paris, Paris, France.; Clinical Research, Biostatistics and Epidemiology Department, AP-HP, Hôpital Bichat, Paris, France.

Subjects: Cytochrome P-450 CYP2D6/Cytochrome P-450 CYP2D6/Cytochrome P-450 CYP2D6/*genetics ; Dopamine Antagonists/Dopamine Antagonists/Dopamine Antagonists/*pharmacokinetics ; Genetic Therapy/Genetic Therapy/Genetic Therapy/*statistics & numerical data

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 Apr; Vol. 10 (4), pp. 340-349.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example.

Authors : Pan X; Certara UK Limited (Simcyp Division), Sheffield, UK.; Abduljalil K

Subjects: Lactation*/Lactation*/Lactation*/metabolism ; Primaquine*/Primaquine*/Primaquine*/metabolism; Infant

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 386-395. Date of Electronic Publication: 2023 Dec 12.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug-drug-gene interaction network.

Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.

Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.

Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration-QTc Analysis.

Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups.

Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity.

Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects.

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate.

Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction.

Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example.

اتصل بنا

اتبع